See more : Page Industries Limited (PAGEIND.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Novan, Inc. (NOVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novan, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Gosun Holding Co., Ltd. (000971.SZ) Income Statement Analysis – Financial Results
- Alamos Gold Inc. (AGI.TO) Income Statement Analysis – Financial Results
- Shinobu Foods Products Co., Ltd. (2903.T) Income Statement Analysis – Financial Results
- Sema4 Holdings Corp. (SMFR) Income Statement Analysis – Financial Results
- Blue Jet Healthcare Limited (BLUEJET.NS) Income Statement Analysis – Financial Results
Novan, Inc. (NOVN)
About Novan, Inc.
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.61M | 2.82M | 4.21M | 4.48M | 5.99M | 2.14M | 0.00 | 0.00 | 112.00K |
| Cost of Revenue | 7.38M | 0.00 | 0.00 | 25.17M | 23.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 16.23M | 2.82M | 4.21M | -20.70M | -17.05M | 2.14M | 0.00 | 0.00 | 112.00K |
| Gross Profit Ratio | 68.74% | 100.00% | 100.00% | -462.25% | -284.66% | 100.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 15.99M | 20.42M | 19.81M | 25.17M | 23.05M | 25.21M | 46.49M | 16.57M | 6.77M |
| General & Administrative | 0.00 | 12.34M | 11.27M | 10.41M | 11.51M | 0.00 | 13.34M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.10M | 12.34M | 11.27M | 10.41M | 11.51M | 13.11M | 13.34M | 9.27M | 5.17M |
| Other Expenses | 1.53M | -136.00K | -712.00K | -419.00K | 72.00K | 0.00 | 127.00K | 0.00 | 0.00 |
| Operating Expenses | 51.62M | 32.62M | 30.37M | 35.17M | 34.55M | 38.33M | 59.83M | 25.83M | 11.94M |
| Cost & Expenses | 59.00M | 32.62M | 30.37M | 35.17M | 34.55M | 38.33M | 59.83M | 25.83M | 11.94M |
| Interest Income | 53.00K | 13.00K | 51.00K | 177.00K | 297.00K | 0.00 | 81.00K | 48.00K | 58.00K |
| Interest Expense | 1.45M | 0.00 | 0.00 | 2.00K | 1.05M | 0.00 | 2.00K | 1.00K | 701.00K |
| Depreciation & Amortization | 1.63M | -384.00K | 6.14M | 2.35M | 1.66M | 1.42M | 757.00K | 631.00K | 462.00K |
| EBITDA | -33.76M | -30.30M | -24.07M | -28.34M | -26.53M | -33.82M | -59.83M | -25.16M | -11.31M |
| EBITDA Ratio | -142.99% | -1,073.67% | -572.10% | -633.06% | -442.80% | -1,580.37% | 0.00% | 0.00% | -10,096.43% |
| Operating Income | -35.39M | -29.92M | -30.21M | -30.69M | -28.56M | -36.19M | -59.83M | -25.83M | -11.83M |
| Operating Income Ratio | -149.90% | -1,060.06% | -718.01% | -685.46% | -476.73% | -1,690.89% | 0.00% | 0.00% | -10,560.71% |
| Total Other Income/Expenses | 4.08M | 223.00K | 921.00K | 47.00K | 0.00 | -942.00K | 127.00K | 48.00K | -1.28M |
| Income Before Tax | -31.31M | -29.69M | -29.29M | -30.64M | -12.67M | -37.13M | -59.70M | -25.79M | -13.10M |
| Income Before Tax Ratio | -132.62% | -1,052.16% | -696.13% | -684.41% | -211.53% | -1,734.91% | 0.00% | 0.00% | -11,699.11% |
| Income Tax Expense | -11.75M | -855.00K | 870.00K | 138.00K | -15.89M | 942.00K | -757.00K | 2.28M | -1.01M |
| Net Income | -19.56M | -28.84M | -30.16M | -30.78M | -12.67M | -37.13M | -59.70M | -28.06M | -11.39M |
| Net Income Ratio | -82.85% | -1,021.86% | -716.80% | -687.49% | -211.53% | -1,734.91% | 0.00% | 0.00% | -10,167.86% |
| EPS | -0.89 | -1.69 | -3.05 | -11.72 | -4.91 | -23.23 | -99.73 | -25.11 | -10.19 |
| EPS Diluted | -0.89 | -1.69 | -3.05 | -11.72 | -4.91 | -23.23 | -99.73 | -25.11 | -10.19 |
| Weighted Avg Shares Out | 22.02M | 17.07M | 9.88M | 2.63M | 2.58M | 1.60M | 598.60K | 1.12M | 1.12M |
| Weighted Avg Shares Out (Dil) | 22.02M | 17.07M | 9.88M | 2.63M | 2.58M | 1.60M | 598.60K | 1.12M | 1.12M |
Results from Novan's Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health
NOVN Stock: 1-For-10 Reverse Split
Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May
Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update
Novan: Q2 2021's SB206 Readout Is Life Or Death For This NO-Based Biotech
NOVN Stock Price Increased Over 10% Pre-Market: Why It Happened
Novan to Present at the H.C. Wainwright Global Life Sciences Conference
NOVN Stock Price Increased Over 28% Intraday: Why It Happened
Novan Reports Full Year 2020 Financial Results and Provides Corporate Update
Novan Completes Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
Source: https://incomestatements.info
Category: Stock Reports